---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-052141"
form_type: "8-K"
ticker: null
cik: "0001735948"
company_name: "Greenbrook TMS Inc."
filed_at: "2024-04-26T23:59:59+00:00"
generated_at: "2026-06-03T06:34:06.459268+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Greenbrook TMS FY 2023 revenue up 10% to $73.8M; net loss narrows to $49.3M

## Summary
- Revenue $73.8M, +10% YoY; regional operating loss improved 56% to $2.7M.
- Net loss $49.3M vs $88.3M; loss per share $1.25 diluted (prior $3.77).
- Restructuring: closed 53 centers, achieved $23M annual cost savings target, $1M charges.
- Expanded Spravato to 82 centers; launched medication management pilot at 9 centers.
- Company changed to domestic issuer; restated quarterly financials from IFRS to US GAAP.

## SEC filing metadata
- accession: 0001104659-24-052141
- form_type: 8-K
- cik: 0001735948
- company_name: Greenbrook TMS Inc.
- filed_at: 2024-04-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735948/000110465924052141/0001104659-24-052141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735948/000110465924052141/tm2411514d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-052141
- JSON: https://secwatch.observer/filing/0001104659-24-052141.json
- Plain text: https://secwatch.observer/filing/0001104659-24-052141.txt

## Key facts
- Earnings Releases
  Greenbrook TMS Inc. reported the fiscal year ended December 31, 2023 results: revenue $73.8 million, net income $49.3 million, EPS $(1.25).
  - Period: the fiscal year ended December 31, 2023
  - Revenue: $73.8 million
  - Net income: $49.3 million
  - EPS: $(1.25)
  - Result: reported results
  source text: are in United States dollars, unless otherwise stated. FISCAL 2023 OPERATIONAL AND FINANCIAL HIGHLIGHTS · Consolidated revenue increased by 10% in Fiscal 2023 to a record $73.8 million, up $7 million as compared to the fiscal year ended December 31, 2022 (“ Fiscal 2022 ”) despite the closure of 53 treatment centers (approximately 29% of active treatment
  evidence_url: https://www.sec.gov/Archives/edgar/data/1735948/000110465924052141/0001104659-24-052141-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.